PeptideStack
5.2kquestions
20kanswers
220users

Is a 31G needle the right choice for drawing dulaglutide at 5 mg/mL?

Asked 28 Oct 2025Modified 9 months agoViewed 8.4k times
19

What I have: a 31G needle · dulaglutide · 5 mg/mL.

I want to know what the trade-off actually is rather than which option is fashionable.

I would rather have a defensible reason than a marginal improvement.

What does each option buy me, and what does it cost me?

needle-gauge
needle-gauge

Gauge and length selection, the trade-off between draw time and tissue trauma, coring risk with larger-bore needles, and why a fixed-needle…

91 questionsinjection-technique
injection-technique

Technique questions: angle, pinch versus flat, aspiration, injection speed, air bubbles, and the handling steps that determine whether you deliver…

96 questionsdead-space
dead-space

The volume trapped in the syringe hub and needle after the plunger bottoms out. It is small in absolute terms and large as a fraction of a small…

117 questionsdulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

200 questions
shareeditfollowflag
JW
askedj_wierzbicki69k14828 Oct 2025

No answers yet

This question has not been answered. It has been viewed 8.4k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.